NUTRA PHARMA CORP (NPHC)
↓ Download CSV- Sector Manufacturing
- Incorporated CA
- Fiscal year ends Dec 31
In fiscal 2025, NUTRA PHARMA CORP reported revenue of $257.6K, up 4.6% from the prior year. The company ran a net loss, with a net margin of -794.8% and a gross margin of 76.3%. It held $584.6K in total assets against $17.41M in total liabilities.
Key ratios (FY2025)
76.3%
Gross margin
-567.7%
Operating margin
-794.8%
Net margin
+4.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $257.6K | $246.3K | $205.6K | $145.8K | $97.7K | $51.9K | $104.4K | $130.6K | — | — |
| Cost of Revenue | $183.7K | $84.8K | $177.5K | $162.8K | $41.3K | — | — | $68.8K | $26.9K | $39.0K |
| Gross Profit | $196.6K | $247.3K | $396.5K | $249.0K | $8.5K | $14.9K | $34.7K | $14.1K | $94.1K | -$54.6K |
| Operating Income | -$1.46M | -$878.4K | -$887.0K | -$1.91M | -$1.99M | -$924.9K | -$1.23M | -$1.88M | -$1.38M | -$2.04M |
| Net Income | -$2.05M | -$1.29M | -$1.39M | $8.18M | -$13.10M | -$769.2K | -$6.59M | -$3.88M | -$4.03M | -$3.45M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $-0.00 | — | — | — | — | — |
| Total Assets | $584.6K | $599.5K | $640.4K | $754.9K | $780.0K | $301.8K | $339.8K | $141.4K | $389.6K | $214.3K |
| Total Liabilities | $17.41M | $15.41M | $14.41M | $13.13M | $21.66M | $11.80M | $12.04M | $6.08M | $5.80M | $4.69M |
| Shareholders' Equity | -$16.83M | -$14.81M | -$13.77M | -$12.38M | -$20.88M | -$11.49M | -$11.70M | -$5.94M | -$5.41M | -$4.48M |
| Cash & Equivalents | $12.2K | $36.4K | $0 | $0 | — | — | — | — | — | — |
| Operating Cash Flow | -$1.16M | -$424.0K | -$550.0K | -$762.4K | -$1.74M | -$878.1K | -$743.7K | -$999.9K | -$1.14M | -$1.36M |
| Capital Expenditures | $26.1K | — | — | $58.0K | $39.0K | $5.9K | — | — | $9.1K | $3.4K |
| Shares Outstanding | 7.10B | 7.10B | 7.06B | 7.04B | 6.77B | 6.96B | 5.88B | 4.05B | 2.03B | 295.07M |